Carla Colombo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6690535/publications.pdf

Version: 2024-02-01

130	6,991	76294 40	62565 80
papers	citations	h-index	g-index

133	133	133	5967
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Limitations of the dichotomized 6-minute walk distance when computing lung allocation score for cystic fibrosis: a 16-year retrospective cohort study. Disability and Rehabilitation, 2023, 45, 2578-2584.	0.9	1
2	Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study. Journal of Cystic Fibrosis, 2022, 21, 220-226.	0.3	20
3	Prevalence and factors associated with urinary incontinence in females with cystic fibrosis: An Italian singleâ€center crossâ€sectional analysis. Pediatric Pulmonology, 2022, 57, 132-141.	1.0	2
4	Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society. Infection, 2022, 50, 671-679.	2.3	20
5	Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over. Journal of Cystic Fibrosis, 2022, , .	0.3	1
6	Improve knowledge and management of thyroid cancer: the role of the endocrinologist in a multidisciplinary team. Minerva Medica, 2022, 112, 689-691.	0.3	1
7	SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy. Journal of Cystic Fibrosis, 2022, 21, e113-e116.	0.3	4
8	Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype. Journal of Cystic Fibrosis, 2022, 21, 850-855.	0.3	12
9	FAM83B is involved in thyroid cancer cell differentiation and migration. Scientific Reports, 2022, 12, .	1.6	0
10	Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists. Health Science Reports, 2022, 5, .	0.6	1
11	Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study. Journal of Cystic Fibrosis, 2022, 21, e221-e231.	0.3	15
12	Clinical evaluation of an evidence-based method based on food characteristics to adjust pancreatic enzyme supplements dose in cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, e33-e39.	0.3	11
13	Association between faecal pH and fat absorption in children with cystic fibrosis on a controlled diet and enzyme supplements dose. Pediatric Research, 2021, 89, 205-210.	1.1	5
14	Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. Journal of Cystic Fibrosis, 2021, 20, 25-30.	0.3	62
15	Three months of COVID-19 in a pediatric setting in the center of Milan. Pediatric Research, 2021, 89, 1572-1577.	1.1	4
16	Liver Disease in Cystic Fibrosis. , 2021, , 93-113.		0
17	Remote support by multidisciplinary teams: A crucial means to cope with the psychological impact of the SARSâ€COVâ€2 pandemic on patients with cystic fibrosis and inflammatory bowel disease in Lombardia. International Journal of Clinical Practice, 2021, 75, e14220.	0.8	6
18	Change in Nutrient and Dietary Intake in European Children with Cystic Fibrosis after a 6-Month Intervention with a Self-Management mHealth Tool. Nutrients, 2021, 13, 1801.	1.7	7

#	Article	IF	Citations
19	SARS-CoV-2 infection in cystic fibrosis: A multicentre prospective study with a control group, Italy, February-July 2020. PLoS ONE, 2021, 16, e0251527.	1.1	18
20	Cystic Fibrosis, New Frontier: Exploring the Functional Connectivity of the Brain Default Mode Network. Comment on Elce et al. Impact of Physical Activity on Cognitive Functions: A New Field for Research and Management of Cystic Fibrosis. Diagnostics 2020, 10, 489. Diagnostics, 2021, 11, 1001.	1.3	1
21	Vaccines in Children with Inflammatory Bowel Disease: Brief Review. Vaccines, 2021, 9, 487.	2.1	4
22	Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. Journal of Cystic Fibrosis, 2021, 20, 566-577.	0.3	34
23	Cytokine storm syndrome in a young patient with cystic fibrosis. Pediatric Pulmonology, 2021, 56, 3435-3437.	1.0	2
24	BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	1.8	36
25	Triple Therapy for Cystic Fibrosis Phe508delâ€“Gating and â€“Residual Function Genotypes. New England Journal of Medicine, 2021, 385, 815-825.	13.9	140
26	Breastfeeding in Cystic Fibrosis: A Systematic Review on Prevalence and Potential Benefits. Nutrients, 2021, 13, 3263.	1.7	2
27	Outcomes of early repeat sweat testing in infants with cystic fibrosis transmembrane conductance regulatorâ€related metabolic syndrome/CF screenâ€positive, inconclusive diagnosis. Pediatric Pulmonology, 2021, 56, 3785-3791.	1.0	11
28	A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres. Journal of Cystic Fibrosis, 2021, 20, 828-834.	0.3	32
29	Chronic infection by nontypeable Haemophilus influenzae fuels airway inflammation. ERJ Open Research, 2021, 7, 00614-2020.	1.1	17
30	Diet as a possible influencing factor in thyroid cancer incidence: the point of view of the nutritionist. Panminerva Medica, 2021, 63, 349-360.	0.2	9
31	Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe. ERJ Open Research, 2021, 7, 00411-2021.	1.1	19
32	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. European Journal of Cancer, 2020, 124, 161-169.	1.3	41
33	Congenital Cytomegalovirus Infection: Update on Diagnosis and Treatment. Microorganisms, 2020, 8, 1516.	1.6	70
34	The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 245.	3.5	27
35	CRMS/CFSPID Subjects Carrying D1152H CFTR Variant: Can the Second Variant Be a Predictor of Disease Development?. Diagnostics, 2020, 10, 1080.	1.3	17
36	The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 868-871.	0.3	74

#	Article	IF	Citations
37	Exercise capacity and ventilation inhomogeneity in cystic fibrosis: A crossâ€sectional study. Pediatric Pulmonology, 2020, 55, 394-400.	1.0	7
38	Impact of COVID-19 on people with cystic fibrosis. Lancet Respiratory Medicine,the, 2020, 8, e35-e36.	5.2	114
39	A case of testicular atrophy associated with cystic fibrosis. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	0
40	A case of testicular atrophy associated with cystic fibrosis. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	0
41	No gender differences in growth patterns in a cohort of children with cystic fibrosis born between 1986 and 1995. Clinical Nutrition, 2019, 38, 1782-1787.	2.3	2
42	Challenges with optimizing nutrition in cystic fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 533-544.	1.0	7
43	Successful ceftazidimeâ€avibactam treatment of postâ€surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis. Transplant Infectious Disease, 2019, 21, e13082.	0.7	19
44	The Relative Contribution of Food Groups to Macronutrient Intake in Children with Cystic Fibrosis: A European Multicenter Assessment. Journal of the Academy of Nutrition and Dietetics, 2019, 119, 1305-1319.	0.4	26
45	Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis. PLoS ONE, 2019, 14, e0213216.	1.1	7
46	Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents. PLoS ONE, 2019, 14, e0225004.	1.1	20
47	Liver Disease in Cystic Fibrosis: Illuminating the Black Box. Hepatology, 2019, 69, 1379-1381.	3.6	11
48	Ventilation inhomogeneity is associated with OGTTâ€derived insulin secretory defects in cystic fibrosis. Pediatric Pulmonology, 2019, 54, 141-149.	1.0	8
49	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. Journal of the National Cancer Institute, 2018, 110, 362-370.	3.0	60
50	MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay. Endocrine, 2018, 61, 36-41.	1.1	13
51	The long and winding road: stem cells for cystic fibrosis. Expert Opinion on Biological Therapy, 2018, 18, 281-292.	1.4	16
52	Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial. Journal of Cystic Fibrosis, 2018, 17, 375-382.	0.3	28
53	Letter regarding the article: â€œMultiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of â€œthyroid-checkedâ€•controlsâ€•by Kern etÂal.. European Journal of Medical Genetics, 2018, 61, 104-105.	0.7	7
54	BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 2787-2795.	0.8	58

#	Article	IF	Citations
55	The role of stem cells in cystic fibrosis disease modeling and drug discovery. Expert Opinion on Orphan Drugs, 2018, 6, 707-717.	0.5	1
56	Delphi poll to assess consensus on issues influencing long-term adherence to treatments in cystic fibrosis among Italian health care professionals. Patient Preference and Adherence, 2018, Volume 12, 2233-2241.	0.8	1
57	Clinical expression of cystic fibrosis in a large cohort of Italian siblings. BMC Pulmonary Medicine, 2018, 18, 196.	0.8	29
58	Gap Junctions Are Involved in the Rescue of CFTR-Dependent Chloride Efflux by Amniotic Mesenchymal Stem Cells in Coculture with Cystic Fibrosis CFBE41o- Cells. Stem Cells International, 2018, 2018, 1-14.	1.2	15
59	Expiratory muscle strength and functional exercise tolerance in adults with cystic fibrosis: a crossâ€sectional study. Physiotherapy Research International, 2018, 23, e1720.	0.7	7
60	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in two young children: the importance of an early diagnosis. Italian Journal of Pediatrics, 2018, 44, 93.	1.0	19
61	Tumor and normal thyroid spheroids: from tissues to zebrafish. Minerva Endocrinology, 2018, 43, 1-10.	0.6	23
62	Genotypeâ€“phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles. Journal of Medical Genetics, 2017, 54, 224-235.	1.5	52
63	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3241-3250.	1.8	80
64	Cystic fibrosis transmembrane conductance-regulator modulators for children. Lancet Respiratory Medicine,the, 2017, 5, 536-537.	5.2	0
65	Innovative approach for self-management and social welfare of children with cystic fibrosis in Europe: development, validation and implementation of an mHealth tool (MyCyFAPP). BMJ Open, 2017, 7, e014931.	0.8	28
66	Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines. Journal of Cystic Fibrosis, 2017, 16, 510-518.	0.3	38
67	Cystic Fibrosisâ€“related Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, 443-448.	0.9	80
68	Caregiver burden and vocational participation among parents of adolescents with CF. Pediatric Pulmonology, 2016, 51, 243-252.	1.0	29
69	Highlights of the ESPENâ€ESPGHANâ€ECFS Guidelines on Nutrition Care for Infants and Children With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 671-675.	0.9	9
70	International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome. Journal of Cystic Fibrosis, 2016, 15, 531-539.	0.3	51
71	Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease. Journal of Pediatrics, 2016, 177, 59-65.e1.	0.9	20
72	ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clinical Nutrition, 2016, 35, 557-577.	2.3	367

#	Article	IF	Citations
73	Bowel ultrasound imaging in patients with cystic fibrosis: Relationship with clinical symptoms and CFTR genotype. Digestive and Liver Disease, 2016, 48, 271-276.	0.4	12
74	ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression. Journal of Gastroenterology, 2016, 51, 271-280.	2.3	45
75	Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 366-371.	0.3	14
76	Age- and Sex-Dependent Distribution of OGTT-Related Variables in a Population of Cystic Fibrosis Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2963-2971.	1.8	15
77	Lumacaftorâ€"Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	13.9	1,308
78	Fetal cell microchimerism: a protective role in autoimmune thyroid diseases. European Journal of Endocrinology, 2015, 173, 111-118.	1.9	16
79	Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer. European Journal of Endocrinology, 2015, 173, 29-36.	1.9	60
80	Cystic fibrosis mortality trend in Italy from 1970 to 2011. Journal of Cystic Fibrosis, 2015, 14, 267-274.	0.3	26
81	Clinical expression of patients with the D1152H CFTR mutation. Journal of Cystic Fibrosis, 2015, 14, 447-452.	0.3	43
82	Interaction between Streptococcus pneumoniae and Staphylococcus aureus in paediatric patients suffering from an underlying chronic disease. International Journal of Immunopathology and Pharmacology, 2015, 28, 497-507.	1.0	7
83	Estimating body composition from skinfold thicknesses and bioelectrical impedance analysis in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 784-791.	0.3	23
84	Two ABCB4 point mutations of strategic NBD-motifs do not prevent protein targeting to the plasma membrane but promote MDR3 dysfunction. European Journal of Human Genetics, 2014, 22, 633-639.	1.4	20
85	Mutation-targeted personalised medicine for cystic fibrosis. Lancet Respiratory Medicine,the, 2014, 2, 863-865.	5.2	6
86	Recurrent pulmonary exacerbations are associated with low fat free mass and low bone mineral density in young adults with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 328-334.	0.3	37
87	Efficacy and tolerability of a new nasal spray formulation containing hyaluronate and tobramycin in cystic fibrosis patients with bacterial rhinosinusitis. Journal of Cystic Fibrosis, 2014, 13, 455-460.	0.3	26
88	Human Rhinovirus Infection in Children with Cystic Fibrosis. Japanese Journal of Infectious Diseases, 2014, 67, 399-401.	0.5	13
89	Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. Lancet Respiratory Medicine,the, 2013, 1, 377-385.	5.2	34
90	Amniotic Mesenchymal Stem Cells: A New Source for Hepatocyte-Like Cells and Induction of CFTR Expression by Coculture with Cystic Fibrosis Airway Epithelial Cells. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-15.	3.0	42

#	Article	IF	Citations
91	Validation of a predictive survival model in Italian patients with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 24-29.	0.3	30
92	Comparison of Calcium and Pentagastrin Tests for the Diagnosis and Follow-Up of Medullary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 905-913.	1.8	95
93	Insulin secretion, nutritional status and respiratory function in cystic fibrosis patients with normal glucose tolerance. Clinical Nutrition, 2012, 31, 118-123.	2.3	24
94	The implementation of standards of care in Europe: State of the art. Journal of Cystic Fibrosis, 2011, 10, S7-S15.	0.3	41
95	Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. Journal of Cystic Fibrosis, 2011, 10, S24-S28.	0.3	151
96	Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. Journal of Cystic Fibrosis, 2011, 10, S29-S36.	0.3	332
97	Clinical Features and Genotypeâ€Phenotype Correlations in Children With Progressive Familial Intrahepatic Cholestasis Type 3 Related to ABCB4 Mutations. Journal of Pediatric Gastroenterology and Nutrition, 2011, 52, 73-83.	0.9	64
98	Influenza A/H1N1 in patients with cystic fibrosis in Italy: a multicentre cohort study. Thorax, 2011, 66, 260-261.	2.7	31
99	Defining DIOS and Constipation in Cystic Fibrosis With a Multicentre Study on the Incidence, Characteristics, and Treatment of DIOS. Journal of Pediatric Gastroenterology and Nutrition, 2010, 50, 38-42.	0.9	143
100	Growth Assessment of Paediatric Patients With CF Comparing Different Auxologic Indicators: A Multicentre Italian Study. Journal of Pediatric Gastroenterology and Nutrition, 2009, 49, 335-342.	0.9	25
101	Genetic Modifiers of Liver Disease in Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2009, 302, 1076.	3.8	256
102	Efficacy and Tolerability of Creon for Children in Infants and Toddlers With Pancreatic Exocrine Insufficiency Caused by Cystic Fibrosis. Pancreas, 2009, 38, 693-699.	0.5	24
103	Liver disease in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2007, 13, 529-536.	1.2	150
104	Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). European Journal of Human Genetics, 2007, 15, 1230-1238.	1.4	85
105	Benefits of breastfeeding in cystic fibrosis: A singleâ€centre followâ€up survey. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 1228-1232.	0.7	43
106	Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transplant International, 2006, 19, 726-731.	0.8	62
107	BMD and Body Composition in Children and Young Patients Affected by Cystic Fibrosis. Journal of Bone and Mineral Research, 2006, 21, 388-396.	3.1	98
108	Dietary and Circulating Polyunsaturated Fatty Acids in Cystic Fibrosis: Are They Related to Clinical Outcomes?. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, 660-665.	0.9	23

#	Article	IF	Citations
109	Liver Disease in Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, S49-S55.	0.9	87
110	Effects of liver transplantation on the nutritional status of patients with cystic fibrosis*. Transplant International, 2005, 18, 246-255.	0.8	51
111	Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatric Pulmonology, 2005, 40, 15-21.	1.0	88
112	Pancreatic Development in Newborn Guinea Pigs Fed Intact or Low-Hydrolyzed Protein Formulas. Journal of Pediatric Gastroenterology and Nutrition, 2005, 41, 644-649.	0.9	3
113	Growth failure in cystic fibrosis: A true need for anabolic agents?. Journal of Pediatrics, 2005, 146, 303-305.	0.9	13
114	Liver involvement in cystic fibrosis: primary organ damage or innocent bystander?. Journal of Hepatology, 2004, 41, 1041-1044.	1.8	35
115	Carbohydrate 19-9 Antigen Is Not a Marker of Liver Disease in Patients with Cystic Fibrosis. Clinical Chemistry and Laboratory Medicine, 2003, 41, 311-6.	1.4	3
116	Influence of Breast Feeding, and Adapted and Hydrolyzed Formulas on Biliary Bile Acids in Newborn Guinea Pigs. Neonatology, 2003, 83, 36-41.	0.9	2
117	Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology, 2002, 36, 1374-1382.	3.6	207
118	Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology, 2002, 36, 1374-1382.	3.6	173
119	Changes in Cesarean Delivery in an Italian University Hospital, 1982-1996: A Comparison with the National Trend. Birth, 1999, 26, 144-148.	1.1	18
120	Liver involvement in cystic fibrosis. Journal of Hepatology, 1999, 31, 946-954.	1.8	51
121	Liver and Biliary Problems in Cystic Fibrosis. Seminars in Liver Disease, 1998, 18, 227-235.	1.8	111
122	Hepatobiliary Disease in Cystic Fibrosis. Seminars in Liver Disease, 1994, 14, 259-269.	1.8	50
123	Analysis of risk factors for the development of liver disease associated with cystic fibrosis. Journal of Pediatrics, 1994, 124, 393-399.	0.9	177
124	Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology, 1992, 15, 677-684.	3.6	123
125	Ursodeoxycholic acid therapy in cystic fibrosisâ€"associated liver disease: A dose-response study. Hepatology, 1992, 16, 924-930.	3.6	127
126	Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology, 1990, 12, 322-334.	3.6	78

#	Article	IF	Citations
127	Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. Journal of Pediatrics, 1990, 117, 482-489.	0.9	143
128	Bile Acid Malabsorption in Cystic Fibrosis With and Without Pancreatic Insufficiency. Journal of Pediatric Gastroenterology and Nutrition, 1984, 3, 556-562.	0.9	22
129	Evaluation of an oral ursodeoxycholic acid load in the assessment of bile acid malabsorption in cystic fibrosis. Digestive Diseases and Sciences, 1983, 28, 306-311.	1.1	18
130	Time Free From Hospitalization in Children and Adolescents With Cystic Fibrosis: Findings From FEV1, Lung Clearance Index and Peak Work Rate. Frontiers in Pediatrics, 0, 10, .	0.9	1